NEWS & INSIGHTS

In December 2020, the FDA granted emergency use authorization for two COVID-19 vaccines. And although there were more than 20 other vaccine candidates undergoing phase 2 or 3 testing as of January 2021, there is more work to be done. Precision’s Marlon Graf and Rifat Tuly identify two components that are required for continued success with COVID-19 vaccine policies, and discuss ways to address them to ensure that the discovery and development of new vaccines for COVID-19 and future pandemics can be sustained in the future.

(more…)

The cell and gene therapy manufacturing skills shortage is slowing the abilities of innovative therapies to reach patients, delaying manufacturing scaleup and increasing learning and development costs. Project Farma’s Anshul Mangal discusses the impact of the cell and gene therapy manufacturing skills shortage, and reviews ways to scale up and bring more therapies to commercialization despite the skills gap.

(more…)

Pharmaceutical manufacturers have accelerated innovation to create vaccines in record time, yet the US is lagging in leveraging effective messages to generate enthusiasm for COVID-19 vaccine adoption. Precision’s Maureen Hennessey and Pam Caputo discuss how using the sacred patient-clinician relationship can help combat the infodemic of vaccine misinformation and disinformation.

(more…)

Researchers have introduced mathematical models of varying complexity over the past several months to capture different aspects of COVID-19’s dynamics, with limited to no implications for healthcare decision-makers. Why? Precision’s Anuj Mubayi and Ross Maclean identify the five myths surrounding COVID-19 mathematical models, and share potential answers regarding the extent to which each myth is addressed in the existing models.

(more…)

In an October 2020 healthcare industry report, the authors projected that biosimilars could hit $80 billion in aggregate sales and provide savings in excess of $100 billion in aggregate over the next five years. Precision’s Dan Danielson joins other industry experts to discuss the impact of biosimilars in 2020 and the forecast for the biosimilars landscape going forward.

(more…)

With the Brexit transition period behind us, the healthcare landscape in the UK is poised for change. Precision’s Dimitrios Tzaras & David Carr discuss 8 regulatory, HTA and commercial initiatives likely to shape UK market access in 2021.

(more…)

While the COVID-19 pandemic seems likely to remain the dominant headline in 2021, a host of other potential occurrences could have big impacts this year. Precision’s Dan Danielson joins a variety of industry experts to discuss what’s ahead in 2021 for healthcare and pharma beyond the pandemic.

(more…)

Recent reforms on price transparency will substantially increase payers’ workloads. The Trump administration and CMS recently released a final rule that will require payers to post documents that include in-network and out-of-network provider rates and in-network drug prices starting in 2022. And in 2023, private insurers will be required to provide negotiated provider cost-sharing estimates and up-front prices to members.

(more…)

Leadership teams from the 2020 Manny Award winners and finalists participated in a comprehensive Q&A forum on a variety of healthcare industry themes and trends.

(more…)

The National Comprehensive Cancer Network (NCCN) recommended zanubrutinib, approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL), for treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The AJMC asked Precision’s Erin Lopata to weigh in on how to respond when a drug is added to NCCN guidelines before the FDA approves the indication.

(more…)